CLB Stock Recent News

REVENUE OF $123.6 MILLION, DOWN 4% SEQUENTIALLY AND 5% YEAR-OVER-YEAR OPERATING INCOME OF $4.4 MILLION; EX-ITEMS, $11.8 MILLION, DOWN 25% SEQUENTIALLY AND 21% YEAR-OVER-YEAR OPERATING MARGINS, EX-ITEMS, OF 10% GAAP EPS OF $0.00; EX-ITEMS, $0.14, DOWN 35% SEQUENTIALLY, AND 25% YEAR-OVER-YEAR FREE CASH FLOW OF $3.9 MILLION, UP OVER 50% YEAR-OVER-YEAR NET DEBT REDUCED BY $4.9 MILLION; DEBT LEVERAGE RATIO REMAINS AT 1.31 COMPANY REPURCHASED 131,598 SHARES OF COMMON STOCK, A VALUE OF $2.0 MILLION COMPANY ANNOUNCES Q1 2025 QUARTERLY DIVIDEND HOUSTON , April 23, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported first quarter 2025 revenue of $123,600,000. Core's operating income was $4,400,000, with earnings per diluted share ("EPS") of $0.00, all in accordance with U.S. generally accepted accounting principles ("GAAP").

Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?

Core Laboratories Inc. (NYSE:CLB ) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Larry Bruno - Chairman and Chief Executive Officer Gwen Gresham - Senior Vice President and Head, Investor Relations Chris Hill - Chief Financial Officer Conference Call Participants Stephen Gengaro - Stifel Josh Jayne - Daniel Energy Partners David Smith - Pickering Energy Partners Operator Good day, and welcome to the Core Laboratories' Fourth Quarter 2024 Earnings Call. All participants will be in listen-only mode.

Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CLB benefits from strong international growth, high-margin projects and an efficient business model. However, stock underperformance, competition and U.S. market challenges pose risks.

Core Laboratories' (CLB) second-quarter 2024 revenues are anticipated to be in the $130-$136 million range, while the operating income is estimated to be in the band of $14.5-$17.3 million.

Core Laboratories' (CLB) first-quarter 2024 revenues are anticipated in the $122-$128 million range, while the operating income is estimated in the band of $11.8-$14.3 million.

Core Laboratories (CLB) came out with quarterly earnings of $0.19 per share, missing the Zacks Consensus Estimate of $0.20 per share. This compares to earnings of $0.20 per share a year ago.

Core Laboratories (CLB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.